Pharmacogenetics

Veterinary Clinics of North America - Small Animal Practice

Volumn 36, Issue 5, 2006, Pages 961-973

  Mealey, Katrina L ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTHRACYCLINE; AVERMECTIN; CELECOXIB; CLOMIPRAMINE; CYCLOSPORIN A; DIGOXIN; DOCETAXEL; DRUG METABOLIZING ENZYME; FLECAINIDE; FLUOXETINE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; IMIPRAMINE; IVERMECTIN; LOPERAMIDE; METOPROLOL; MILBEMYCIN; MOXIDECTIN; NEUROLEPTIC AGENT; PACLITAXEL; PHENYTOIN; PROPRANOLOL; QUINIDINE; SELAMECTIN; SUXAMETHONIUM; TIMOLOL; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; GENE MUTATION; GENETIC VARIABILITY; HISTORY; HUMAN; HUMAN GENOME; NONHUMAN; PHARMACOGENETICS; REVIEW; SINGLE DRUG DOSE;

ANIMALS; GENOME; PHARMACOGENETICS; VETERINARY DRUGS; VETERINARY MEDICINE;

EID: 33748568746     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2006.05.006     Document Type: Review

References (47)

1. Hochstein P. Glucose-6-phosphate dehydrogenase deficiency: mechanisms of drug-induced hemolysis. Exp Eye Res 11 3 (1971) 389-395
2. Patel J., and Mitra A.K. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. Pharmacogenomics 2 4 (2001) 401-415
3. Scordo M.G., and Spina E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 3 2 (2002) 201-218
4. Roninson I.B. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 43 1 (1992) 95-102
5. Thiebaut F., Tsuruo T., Hamada H., et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84 21 (1987) 7735-7738
6. Schinkel A.H., Wagenaar E., van Deemter L., et al. Absence of the Mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96 4 (1995) 1698-1705
7. Sills GJ, Kwan P, Butler E, et al. P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in Mdr1a knockout mice. 2002;3(5):427-32.
8. Verstuyft C., Schwab M., Schaeffeler E., et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 58 12 (2003) 809-812
9. Kerb R., Aynacioglu A.S., Brockmoller J., et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 1 3 (2001) 204-210
10. Ginn P.E. Immunohistochemical detection of P-glycoprotein in formalin-fixed and paraffin-embedded normal and neoplastic canine tissues. Vet Pathol 33 5 (1996) 533-541
11. Mealey K.L., Barhoumi R., Rogers K., et al. Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line. Cancer Lett 126 2 (1998) 187-192
12. Page R.L., Hughes C.S., Huyan S., et al. Modulation of P-glycoprotein-mediated doxorubicin resistance in canine cell lines. Anticancer Res 20 5B (2000) 3533-3538
13. McEntee M., Silverman J.A., Rassnick K., et al. Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. Vet Comp Oncol 2 1 (2003) 105-112
14. Mealey K.L., Bentjen S.A., Gay J.M., et al. Ivermectin sensitivity in collies is associated with a deletion mutation of the Mdr1 gene. Pharmacogenetics 11 8 (2001) 727-733
15. Mealey K.L., Bentjen S.A., and Waiting D.K. Frequency of the mutant MDR1 Allele associated with ivermectin sensitivity in a sample population of collies from the northwestern United States. Am J Vet Res 63 4 (2002) 479-481
16. Neff M.W., Robertson K.R., Wong A.K., et al. Breed distribution and history of canine Mdr1-1Δ, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc Natl Acad Sci USA 101 (2004) 11725-11730
17. Tranquilli W.J., Paul A.J., and Todd K.S. Assessment of toxicosis induced by high-dose administration of milbemycin oxime in collies. Am J Vet Res 52 7 (1991) 1170-1172
18. Hugnet C., Cadore J.L., Buronfosse F., et al. Loperamide poisoning in the dog. Vet Hum Toxicol 38 1 (1996) 31-33
19. Ericsson C.D., and Johnson P.C. Safety and efficacy of loperamide. Am J Med 88 6A (1990) 10S-14S
20. Wandel C., Kim R., Wood M., et al. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96 4 (2002) 913-920
21. Sartor L.L., Bentjen S.A., Trepanier L., et al. Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity. J Vet Intern Med 18 1 (2004) 117-118
22. Choo E.F., Leake B., Wandel C., et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28 6 (2000) 655-660
23. Katagiri A., Tomita Y., Nishiyama T., et al. Immunohistochemical detection of P-glycoprotein and GSTP1-1 in testis cancer. Br J Cancer 68 1 (1993) 125-129
24. Young A.M., Allen C.E., and Audus K.L. Efflux transporters of the human placenta. Adv Drug Deliv Rev 55 1 (2003) 125-132
25. Wing J.P. Blood protein polymorphisms in Jewish populations. Hum Hered 24 4 (1974) 323-344
26. Cascorbi I. Pharmacogenetics of cytochrome P4502D6. Genetic background and clinical implication. Eur J Clin Invest 33 Suppl 2 (2003) 17-22
27. Hay Kraus B.L., Greenblatt D.J., Venkatakrishnan K., et al. Evidence for propofol hydroxylation by cytochrome P4502B11 in canine liver microsomes: breed and gender differences. Xenobiotica 30 6 (2000) 575-588
28. Court M.H., Hay-Kraus B.L., Hill D.W., et al. Propofol hydroxylation by dog liver microsomes. Assay development and dog breed differences. Drug Metab Dispos 27 11 (1999) 1293-1299
29. Paulson S.K., Engel L., Reitz B., et al. Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor celecoxib. Drug Metab Dispos 27 10 (1999) 1133-1142
30. Tenmizu D., Endo Y., Noguchi K., et al. Identification of the novel canine CYP1A2 1117 C > T SNP causing protein deletion. Xenobiotica 34 9 (2004) 835-846
31. Tanaka N., Shinkyo R., Sakaki T., et al. Cytochrome P450 2E polymorphism in feline liver. Biochim Biophys Acta 1726 (2005) 194-205
32. Theilmann J.L., Skow L.C., Baker J.F., et al. Restriction fragment length polymorphisms for growth hormone, prolactin, osteonectin, alpha crystallin, gamma crystallin, fibronectin and 21-steroid hydroxylase in cattle. Anim Genet 20 3 (1989) 257-266
33. Collins J.M. Inter-species differences in drug properties. Chem Biol Interact 134 3 (2001) 237-242
34. Kidd L.B., Salavaggione O.E., Szumlanski C.L., et al. Thiopurine methyltransferase activity in red blood cells of dogs. J Vet Intern Med 18 2 (2004) 214-218
35. Kiso S., Cai S.H., Kitaichi K., et al. Inhibitory effect of erythromycin on P-glycoprotein-mediated biliary excretion of doxorubicin in rats. Anticancer Res 20 5A (2000) 2827-2834
36. Song S., Suzuki H., Kawai R., et al. Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. Drug Metab Dispos 27 6 (1999) 689-694
37. Mealey K.L., Northrup N.C., and Bentjen S.A. Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. J Am Vet Med Assoc 223 10 (2003) 1453-1455 1434
38. Tribut O., Lessard Y., Reymann J.M., et al. Pharmacogenomics. Med Sci Monit 8 7 (2002) RA152-RA163
39. Ito H., Nara H., Inoue-Murayama M., et al. Allele frequency distribution of the canine dopamine receptor D4 gene exon III and I in 23 breeds. J Vet Med Sci 66 7 (2004) 815-820
40. Trepanier L.A. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog. J Vet Pharmacol Ther 27 3 (2004) 129-138
41. Spielberg S.P. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm 24 5 (1996) 509-519
42. Becquemont L. Clinical relevance of pharmacogenetics. Drug Metab Rev 35 4 (2003) 277-285
43. Schwab M., Eichelbaum M., and Fromm M.F. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43 (2003) 285-307
44. Fromm M.F. Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology 181/182 (2002) 299-303
45. Sakaeda T., Nakamura T., and Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 25 11 (2002) 1391-1400
46. Sakaeda T., Nakamura T., and Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4 4 (2003) 397-410
47. Marzolini C., Paus E., Buclin T., et al. Polymorphisms in human MDR1 (P-glycoprotein). Recent advances and clinical relevance. Clin Pharmacol Ther 75 1 (2004) 13-33